- Lobbying
- Lobbying by Enzyvant Therapeutics GmbH
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
John Herzog | Health Aide, Senator Lamar Alexander; Special Assistant to the Assistant to the President for Legislative Affairs, Executive Office of the President Health Aide, Sen. Lamar Alexander; Special Assistant to the Assistant to the President for Legislative Affairs, Executive Office of the President |
Keith Studdard | Legislative Director, Rep. Marsha Blackburn |
John Ray | Legislative Assistant, Rep. Mike Kelly |
Kelsey Carlson | Special Assistant, National Security Council; Special Assistant, International Trade Administration, Dept of Commerce; Policy Advisor, Office of the Deputy Chief of Staff, Executive Office of the President; Confidential Assistant, Dept of Commerce |
Jeffrey Kimbell | n/a |
Jodie Lockhart | n/a |
Kenneth Hodge | n/a |
David Rudloff | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q4 Report
Q3 Report
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Office of Management & Budget (OMB)
Health & Human Services - Dept of (HHS)
Centers For Medicare and Medicaid Services (CMS)
Type of Issue
Registration
Issue(s) they said they’d lobby about: Pharmaceutical and healthcare issues.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate